Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1

3(50.0%)

Phase 2

2(33.3%)

Phase 3

1(16.7%)

6Total

Phase 1(3)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06530966Phase 1Completed

Phase I Study of ICP-332 in Healthy Subjects

Role: lead

NCT07480863Phase 2Active Not Recruiting

Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL

Role: collaborator

NCT06351527Phase 1Recruiting

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies

Role: lead

NCT06363994Phase 3Recruiting

A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL

Role: lead

NCT05978739Phase 2Unknown

Evaluating Different Doses of Orelabrutinib in MCL

Role: lead

NCT05537987Phase 1Unknown

Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors

Role: lead

All 6 trials loaded